Merus Bv Stock Today
| MRUS Stock | USD 44.97 0.90 1.96% |
Performance0 of 100
| Odds Of DistressLess than 46
|
Merus BV is selling for under 44.97 as of the 28th of November 2024; that is 1.96 percent down since the beginning of the trading day. The stock's lowest day price was 44.75. Merus BV has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Merus BV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of May 2016 | Category Healthcare | Classification Health Care |
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. Merus NV is traded on NASDAQ Exchange in the United States.. The company has 68.46 M outstanding shares of which 8.66 M shares are now shorted by private and institutional investors with about 23.82 trading days to cover. More on Merus BV
Moving against Merus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Merus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Hui Liu | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Merus BV (MRUS) is traded on NASDAQ Exchange in USA. It is located in Uppsalalaan 17, Utrecht, Netherlands, 3584 CT and employs 172 people. Merus BV is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.14 B. Merus BV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 68.46 M outstanding shares of which 8.66 M shares are now shorted by private and institutional investors with about 23.82 trading days to cover.
Merus BV currently holds about 376.11 M in cash with (142.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.2.
Check Merus BV Probability Of Bankruptcy
Ownership AllocationThe majority of Merus BV outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Merus BV to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Merus BV. Please pay attention to any change in the institutional holdings of Merus BV as this could imply that something significant has changed or is about to change at the company.
Check Merus Ownership Details
Merus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wellington Management Company Llp | 2024-06-30 | 1.7 M | |
| Holocene Advisors, Lp | 2024-09-30 | 1.6 M | |
| Driehaus Capital Management Llc | 2024-06-30 | 1.6 M | |
| Blackrock Inc | 1.5 M | ||
| T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | |
| Venbio Select Advisor Llc | 2024-09-30 | 1.4 M | |
| Polar Capital Holdings Plc | 2024-06-30 | 1.3 M | |
| Hhg Plc | 2024-06-30 | 1 M | |
| Rock Springs Capital Management Lp | 2024-06-30 | 1 M | |
| Fmr Inc | 2024-09-30 | 6.9 M | |
| Rtw Investments, Llc | 2024-06-30 | 4.2 M |
Merus BV Historical Income Statement
Merus Stock Against Markets
Merus BV Corporate Management
| Peter JD | Company EVP | Profile | |
| Ashley PharmD | Senior Affairs | Profile | |
| Kathleen Farren | IR Officer | Profile | |
| Gregory Perry | Chief Officer | Profile | |
| Hennie Hoogenboom | CoFounder Advisor | Profile | |
| Alexander Bakker | Chief VP | Profile | |
| Cecilia Geuijen | Chief VP | Profile |
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.